Strategic collaboration Opportunities to partner with renowned experts and institutions (Robert Benezra, Sloan Kettering Lab) could accelerate AGX-A development and expand access to cutting-edge oncology and ophthalmology targets.

Narrow focus opportunities Target opportunities around Id protein inhibitors in cancers such as cholangiocarcinoma and age-related macular degeneration, where AngioGenex has validated leads and differentiation potential.

Early-stage leverage With a small team and early revenue under one million, there is room to offer contract research, target validation services, or co-development models to extend runway and attract strategic investors.

Funding and grants Pursue non-dilutive funding, grants, and partnerships to scale preclinical programs, leveraging their platform technologies to de-risk partnerships and attract larger pharma collaborators.

Competitor positioning Position as a specialized Id-protein inhibitor platform company with unique collaborations and a lean, agile development path that complements larger biopharma players in oncology and ophthalmology.